Unknown

Dataset Information

0

A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs.


ABSTRACT: Poly(ethylene glycol)-block-poly(D,L-lactic acid) (PEG-b-PLA) micelles have a proven capacity for drug solubilization and have entered phase III clinical trials as a substitute for Cremophor EL in the delivery of paclitaxel in cancer therapy. PEG-b-PLA is less toxic than Cremophor EL, enabling a doubling of paclitaxel dose in clinical trials. We show that PEG-b-PLA micelles act as a 3-in-1 nanocontainer for paclitaxel, 17-allylamino-17-demethoxygeldanamycin (17-AAG), and rapamycin for multiple drug solubilization. 3-in-1 PEG-b-PLA micelles were ca. 40 nm in diameter; dissolved paclitaxel, 17-AAG, and rapamycin in water at 9.0 mg/mL; and were stable for 24 h at 25 °C. The half-life for in vitro drug release (t(1/2)) for 3-in-1 PEG-b-PLA micelles was 1-15 h under sink conditions and increased in the order of 17-AAG, paclitaxel, and rapamycin. The t(1/2) values correlated with log P(o/w) values, implicating a diffusion-controlled mechanism for drug release. The IC(50) value of 3-in-1 PEG-b-PLA micelles for MCF-7 and 4T1 breast cancer cell lines was 114 ± 10 and 25 ± 1 nM, respectively; combination index (CI) analysis showed that 3-in-1 PEG-b-PLA micelles exert strong synergy in MCF-7 and 4T1 breast cancer cell lines. Notably, concurrent intravenous (iv) injection of paclitaxel, 17-AAG, and rapamycin using 3-in-1 PEG-b-PLA micelles was well-tolerated by FVB albino mice. Collectively, these results suggest that PEG-b-PLA micelles carrying paclitaxel, 17-AAG, and rapamycin will provide a simple yet safe and efficacious 3-in-1 nanomedicine for cancer therapy.

SUBMITTER: Shin HC 

PROVIDER: S-EPMC4896148 | biostudies-literature | 2011 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

A 3-in-1 polymeric micelle nanocontainer for poorly water-soluble drugs.

Shin Ho-Chul HC   Alani Adam W G AW   Cho Hyunah H   Bae Younsoo Y   Kolesar Jill M JM   Kwon Glen S GS  

Molecular pharmaceutics 20110623 4


Poly(ethylene glycol)-block-poly(D,L-lactic acid) (PEG-b-PLA) micelles have a proven capacity for drug solubilization and have entered phase III clinical trials as a substitute for Cremophor EL in the delivery of paclitaxel in cancer therapy. PEG-b-PLA is less toxic than Cremophor EL, enabling a doubling of paclitaxel dose in clinical trials. We show that PEG-b-PLA micelles act as a 3-in-1 nanocontainer for paclitaxel, 17-allylamino-17-demethoxygeldanamycin (17-AAG), and rapamycin for multiple d  ...[more]

Similar Datasets

| S-EPMC6594770 | biostudies-literature
| S-EPMC5918157 | biostudies-literature
| S-EPMC3760723 | biostudies-literature
| S-EPMC6781556 | biostudies-literature
| S-EPMC8173698 | biostudies-literature
| S-EPMC9804101 | biostudies-literature
| S-EPMC4113620 | biostudies-other
| S-EPMC3026907 | biostudies-literature
| S-EPMC5899018 | biostudies-literature
| S-EPMC9864024 | biostudies-literature